HIV vaccine - GeneCure

Drug Profile

HIV vaccine - GeneCure

Alternative Names: HIVAX; Replication-defective HIV-1 vaccine (HIVAX™) - GeneCure Biotechnologies

Latest Information Update: 01 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GeneCure
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 01 Apr 2016 Phase-I development is ongoing in USA
  • 13 May 2015 Interim efficacy and adverse events data from a phase I trial in HIV-1 infections released by Genecure
  • 02 Sep 2011 Phase-I clinical trials in HIV-1 infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top